1Hennessy BT, Gauthier AM, Michaud LB, et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature[J]. Ann Oncol, 2005, 16: 1289-1296.
2Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory Metastatic breast cancer[J]. J Clin Oncol, 1999, 17 (2): 485-493.
4Mortimer JE, Lauman MK, Tan B, et al. Pyridoxine treatment and prevention of hand-and-foot syndrome in patients receiving capecitabine[J]. J Oncol Pharm Practice, 2003, 9: 161-166.
4[1]Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol, 1999, 17 (2):485
5[2]Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised,phase Ⅱ trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreatedwith anthracyclines. Br J Cancer, 2002, 86 (9):1367
6[3]Meta-analysis goup in cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced coleorectal cancer. J Clin Oneol. 1998, 16:301
7[4]Meta-analysis group in carcer. Toxicity of fiuorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol, 1998, 16:3537
8[5]Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Inter Med, 1984, 101 :798
9[6]Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase Ⅱ study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol, 1999, 17 (2) :485
10[7]Vukelja SJ, Lombardo FA, James WD, et al. Pyridoxine for the palar-plantar erythrodysesthesia syndrome. Ann Inter Med,1989, 111:688
